HLS Therapeutics Inc. updated consolidated revenue guidance for the full year 2024. for the year, the company is lowering its full year consolidated revenue guidance to a range of $60 million - $62 million from $63.5 million -$66.5 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 CAD | -7.00% | -4.12% | -5.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.82% | 86.75M | |
+23.41% | 74.04B | |
-1.81% | 24.18B | |
+3.42% | 8.46B | |
+9.92% | 8.34B | |
-23.66% | 7.64B | |
+13.06% | 5.33B | |
+2.27% | 4.12B | |
-6.90% | 3.92B | |
+3.99% | 3.89B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024